Halozyme Therapeutics HALO Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's increase (decrease) in prepaid expense and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's increase (decrease) in prepaid expense and other assets?
- Halozyme Therapeutics (HALO) reported increase (decrease) in prepaid expense and other assets of $9.11M in Q1 2026.
- How has Halozyme Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
- Halozyme Therapeutics's increase (decrease) in prepaid expense and other assets increased by 82.3% year-over-year, from $5M to $9.11M.
- What does increase (decrease) in prepaid expense and other assets mean?
- This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.